Novavax has secured a transformative partnership with Sanofi, which includes $1.2 billion in potential payments and critical commercial support. The company’s COVID-19 vaccine targets the JN.

Per the deal terms, Sanofi took a minority stake in NVAX (a $70 million equity investment), will gain rights to co-market Novavax’s COVID-19 vaccine globally, and will have the sole license to ...

Gaithersburg, Maryland-based Novavax received ... it struck a $1.2 billion licensing agreement with French drugmaker Sanofi to co-commercialize the combination vaccine. Get breaking news and ...

PR Newswire • 16 days ago Novavax 2024-2025 Formula COVID-19 Vaccine Now Authorized ... Welcomes Recent Announcement by Novavax of Licensing Agreement with Sanofi Stresses Significant Value ...

Novavax NVAX announced that the FDA granted emergency use authorization (EUA) to an updated version of its protein-based COVID-19 vaccine for ... The deal with Sanofi breathes new life into ...

RSV and Meningitis / travel vaccines will be the COVID vaccine developed by Novavax (NVAX) - as I wrote in a recent note on Novavax: By the terms of the deal, Sanofi made a $500m upfront payment ...

Struggling biotech Novavax (NASDAQ: NVAX) was a hot buy a few years ago as it was in the midst of developing a vaccine ... licensing agreement which Novavax announced with healthcare giant Sanofi ...

The approval was based on non-clinical data that showed Novavax's updated vaccine provides protection ... including revenue recognition of Sanofi Payment, compared to the consensus of $936.38 ...

Regulators approve its updated COVID-19 vaccine It may seem ... If not for a licensing agreement which Novavax announced with healthcare giant Sanofi earlier this year to develop products ...

Per the deal terms, Sanofi took a minority stake in NVAX (a $70 million equity investment), will gain rights to co-market Novavax’s COVID-19 vaccine globally, and will have the sole license to develop ...